A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis

Abroad (travel likely)RecruitingPHASE3

Conditions

Secondary Hyperparathyroidism

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Universitair Ziekenhuis Gent, Ghent, Belgium

  • Fakultni nemocnice v Motole, Prague, Czechia

  • Hospices Civils de Lyon Hopital Femme Mere Enfant, Bron, France

  • Hopital Armand Trousseau, Paris, France

  • Kindernierenzentrum Bonn, Bonn, Germany

  • Universitaetsklinikum Koeln, Cologne, Germany

  • Universitaetsklinikum Hamburg Eppendorf, Hamburg, Germany

  • Medizinische Hochschule Hannover, Hanover, Germany

  • Universitaetsklinikum Heidelberg, Zentrum fuer Kinder und Jugendmedizin, Heidelberg, Germany

  • General Children Hospital Panagioti and Aglaias Kyriakou, Athens, Greece

  • Ippokrateio General Hospital of Thessaloniki, Thessaloniki, Greece

  • Semmelweis Egyetem, Budapest, Hungary

  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Altalanos Orvostudomanyi Kar, Szeged, Hungary

  • Azienda Ospedaliera Universitaria Meyer, Florence, Italy

  • Childrens Hospital, Affiliate of Vilnius University Hospital Santaros Klinikos, Vilinus, Lithuania

  • Uniwersytecki Szpital Dzieciecy w Krakowie, Krakow, Poland

  • Unidade Local de Saude de Santo Antonio, EPE - Hospital de Santo Antonio, Porto, Portugal

  • Hospital Universitario Virgen del Rocio, Seville, Andalusia, Spain

  • Hospital Universitari Vall d Hebron, Barcelona, Catalonia, Spain

  • Royal Hospital for Sick Children, Glasgow, United Kingdom

  • Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

  • Great Ormond Street Hospital for Children, London, United Kingdom

  • University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom

Study leads
  • MD

    Study Director

    Amgen